Literature DB >> 16598816

Gene therapy for HIV infection: what does it need to make it work?

Dorothee von Laer1, Susanne Hasselmann, Klaus Hasselmann.   

Abstract

The efficacy of antiviral drug therapy for HIV infection is limited by toxicity and viral resistance. Thus, alternative therapies need to be explored. Several gene therapeutic strategies for HIV infection have been developed, but in clinical testing therapeutically effective levels of the transgene product were not achieved. This review focuses on the determinants of therapeutic efficacy and discusses the potential and also the limits of current gene therapy approaches for HIV infection. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16598816     DOI: 10.1002/jgm.908

Source DB:  PubMed          Journal:  J Gene Med        ISSN: 1099-498X            Impact factor:   4.565


  19 in total

Review 1.  The use of cell-delivered gene therapy for the treatment of HIV/AIDS.

Authors:  Geoff P Symonds; Helen A Johnstone; Michelle L Millington; Maureen P Boyd; Bryan P Burke; Louis R Breton
Journal:  Immunol Res       Date:  2010-12       Impact factor: 2.829

2.  Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment.

Authors:  Jinyun Yuan; Jianbin Wang; Karen Crain; Colleen Fearns; Kenneth A Kim; Kevin L Hua; Philip D Gregory; Michael C Holmes; Bruce E Torbett
Journal:  Mol Ther       Date:  2012-01-24       Impact factor: 11.454

3.  Bone marrow transplant muffles HIV.

Authors: 
Journal:  Nat Med       Date:  2009-04       Impact factor: 53.440

4.  Combinatorial evaluation of cations, pH-sensitive and hydrophobic moieties for polymeric vector design.

Authors:  Sharon Y Wong; Nimil Sood; David Putnam
Journal:  Mol Ther       Date:  2009-01-13       Impact factor: 11.454

5.  Gene therapy strategies: can we eradicate HIV?

Authors:  Jan van Lunzen; Boris Fehse; Joachim Hauber
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

6.  Gene transfer of two entry inhibitors protects CD4⁺ T cell from HIV-1 infection in humanized mice.

Authors:  N Y Petit; C Baillou; A Burlion; K Dorgham; B Levacher; C Amiel; V Schneider; F M Lemoine; G Gorochov; G Marodon
Journal:  Gene Ther       Date:  2015-10-21       Impact factor: 5.250

7.  Secreted antiviral entry inhibitory (SAVE) peptides for gene therapy of HIV infection.

Authors:  Lisa Egerer; Andreas Volk; Joerg Kahle; Janine Kimpel; Frances Brauer; Felix G Hermann; Dorothee von Laer
Journal:  Mol Ther       Date:  2011-03-01       Impact factor: 11.454

8.  In silico modeling indicates the development of HIV-1 resistance to multiple shRNA gene therapy differs to standard antiretroviral therapy.

Authors:  Tanya Lynn Applegate; Donald John Birkett; Glen John Mcintyre; Angel Belisario Jaramillo; Geoff Symonds; John Michael Murray
Journal:  Retrovirology       Date:  2010-10-09       Impact factor: 4.602

9.  Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells.

Authors:  Ronald T Mitsuyasu; Thomas C Merigan; Andrew Carr; Jerome A Zack; Mark A Winters; Cassy Workman; Mark Bloch; Jacob Lalezari; Stephen Becker; Lorna Thornton; Bisher Akil; Homayoon Khanlou; Robert Finlayson; Robert McFarlane; Don E Smith; Roger Garsia; David Ma; Matthew Law; John M Murray; Christof von Kalle; Julie A Ely; Sharon M Patino; Alison E Knop; Philip Wong; Alison V Todd; Margaret Haughton; Caroline Fuery; Janet L Macpherson; Geoff P Symonds; Louise A Evans; Susan M Pond; David A Cooper
Journal:  Nat Med       Date:  2009-02-15       Impact factor: 53.440

10.  Efficient entry inhibition of human and nonhuman primate immunodeficiency virus by cell surface-expressed gp41-derived peptides.

Authors:  R C Zahn; F G Hermann; E-Y Kim; M D Rett; S M Wolinsky; R P Johnson; F Villinger; D von Laer; J E Schmitz
Journal:  Gene Ther       Date:  2008-05-01       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.